Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Universidade de São Paulo, Ribeirão Preto, Brazil.
Eur J Pharm Sci. 2011 Dec 18;44(5):580-8. doi: 10.1016/j.ejps.2011.10.005. Epub 2011 Oct 8.
Because of the potential protective role of leukotrienes (LTs) in histoplasmosis and the therapeutic and prophylactic effects of cell-free antigens from Histoplasmacapsulatum (CFAgs), the aim of this study was to develop and characterise biodegradable LTB(4)/CFAgs-loaded microspheres (MS) that could promote cellular activation for future immunisation purposes. LTB(4)/CFAgs-loaded MS that were developed through a double emulsion/extraction process were characterised according to their size, zeta potential, morphology, entrapment efficiency and in vitro release kinetics. We evaluated the uptake of LTB(4)/CFAgs-loaded MS by bone marrow derived-macrophages (BMDM). The TNF-α and chemokines, and nitrite production, in the supernatant of BMDM cultures were analysed by enzyme-linked immunosorbent assay (ELISA) and Griess reaction, respectively. We found an instantaneous release of CFAgs and a prolonged release of LTB(4) from the poly-(d,l-lactide-co-glycolide) (PLGA) MS. The microencapsulation process did not alter the zeta potential nor the spherical morphology of the MS. The appropriate size of the LTB(4)/CFAgs-loaded MS (smaller than 10μm) enabled the efficient uptake by BMDM and also induced TNF-α, CXCL1/KC, CCL2/MCP-1, CCL5/RANTES and nitrite oxide release by these cells. In conclusion, the biodegradable LTB(4)/CFAgs-loaded MS were able to efficiently activate murine BMDM and thereby have the potential to be used in an effective vaccine against H. capsulatum infection.
由于白三烯 (LTs) 在组织胞浆菌病中的潜在保护作用以及荚膜组织胞浆菌 (CFAgs) 无细胞抗原的治疗和预防作用,本研究旨在开发和表征可促进细胞活化的可生物降解 LTB(4)/CFAgs 载药微球 (MS),用于未来的免疫接种目的。通过双乳液/萃取工艺开发的 LTB(4)/CFAgs 载药 MS 根据其大小、Zeta 电位、形态、包封效率和体外释放动力学进行了表征。我们评估了骨髓来源巨噬细胞 (BMDM) 对 LTB(4)/CFAgs 载药 MS 的摄取。通过酶联免疫吸附试验 (ELISA) 和 Griess 反应分别分析 BMDM 培养物上清液中的 TNF-α 和趋化因子以及亚硝酸盐的产生。我们发现 CFAgs 立即释放,LTB(4) 从聚 (D,L-丙交酯-co-乙交酯) (PLGA) MS 中持续释放。微囊化过程并未改变 MS 的 Zeta 电位或球形形态。适当大小的 LTB(4)/CFAgs 载药 MS(小于 10μm)能够有效地被 BMDM 摄取,并诱导这些细胞释放 TNF-α、CXCL1/KC、CCL2/MCP-1、CCL5/RANTES 和亚硝酸盐。总之,可生物降解的 LTB(4)/CFAgs 载药 MS 能够有效地激活鼠源 BMDM,因此有可能用于有效的荚膜组织胞浆菌感染疫苗。